Cushing's disease in dogs: Cabergoline treatment

Research in Veterinary Science

Volumn 85, Issue 1, 2008, Pages 26-34

  Castillo, V A ^a   Gomez N V ^a   Lalia, J C ^a   Cabrera Blatter, M F ^a   Garcia J D ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Cabergoline; Corticotrophinoma; Cushing's disease; D2 dopamine receptor; Hyperadrenocorticism

Indexed keywords

ALPHA INTERMEDIN; CABERGOLINE; CORTICOTROPIN; CREATININE; HYDROCORTISONE; KETOCONAZOLE;

ARTICLE; CONTROLLED STUDY; CUSHING DISEASE; DOG DISEASE; DRUG RESPONSE; FEMALE; FOLLOW UP; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; LONGITUDINAL STUDY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; STATISTICAL SIGNIFICANCE; SURVIVAL; TREATMENT DURATION; TUMOR VOLUME;

ADRENOCORTICOTROPIC HORMONE; ALPHA-MSH; ANIMALS; DOG DISEASES; DOGS; DOPAMINE AGONISTS; ERGOLINES; FEMALE; KETOCONAZOLE; MALE; PITUITARY ACTH HYPERSECRETION; TIME FACTORS;

CANIS FAMILIARIS;

EID: 43649097164     PISSN: 00345288     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rvsc.2007.08.009     Document Type: Article

References (66)

1. Abs R., Verhelst J., Maiter D., Van Acker K., Nobels F., Coolens J.L., et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. Journal of Clinical Endocrinology and Metabolism 833 (1998) 74-78
2. Antakly T., Mercille S., and Cote J.P. Tissue-specific dopaminergic regulation of the glucocorticoid receptor in the rat pituitary. Endocrinology 120 (1987) 1558-1562
3. Asa S., and Ezzat S. The cytogenesis and pathogenesis of pituitary adenomas. Endocrinology Reviews 19 (1998) 798-827
4. Bevan J.S., Webster J., Burke C.W., and Scanlon M.F. Dopamine agonists and pituitary tumor shrinkage. Endocrinology Review 13 (1992) 220-240
5. Boscaro M., Barzon L., Fallo F., and Sonino N. Cushing's syndrome. The Lancet 357 (2001) 783-790
6. Bosje J., Rijnberk A., Mol J., Voorhout G., and Kooistra H. Plasma concentrations of ACTH precursors correlate with pituitary size and resistance to dexamethasone in dogs with pituitary-dependent hyperadrenocorticism. Domestic Animal Endocrinology 22 (2002) 201-210
7. Bruyette, D.S., 1995. Canine pituitary-dependent hyperadrenocorticism: a spontaneous animal model for neurodegenerative disorders and their treatment with l-deprenyl. In: P. Yu, K. Tipton, A. Boulton, (Eds.), Current Neurochemical and pharmacological aspects of biogenic amines, Progres in Brain Research, vol. 106, pp. 207-215.
8. Caron M.G., Beaulieu M., Raymond V., Gagne B., Drouin J., Lefkowitz R.J., and Labrie F. Dopaminergic receptors in the anterior pituitary gland. Journal Biololy Chemistry 253 (1978) 2244-2253
9. Castillo V.A., Lalia J.C., Casal J., Casal G., Esarte M., Mira G., Rodriguez M., and Marquez A. Aminoglutetimide: alternativa terapéutica en caninos con Enfermedad de Cushing (hipófiso-dependiente). Avances en Medicina Veterinaria 11 (1996) 93-96
10. Castillo V.A., Giacomini D.P., Páez-Pered M., Stalla J., Labeur M., Theodoropoulou M., Holsboer F., Grossman A., Stalla G., and Arzt E. Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology 174 (2006) 4438-4444
11. Casulari L., Naves L., Mello P., Neto A., and Papadia C. Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Hormone Research 62 (2004) 300-305
12. Colao A., Lombardi G., and Annunziato L. Cabergoline. Experimental Opinion Pharmacotherapy 1 (2000) 555-574
13. Colao A., Di Sarno A., Pivonello R., Di Somma C., and Lombardi G. Dopamine receptor agonists for treating prolactinomas. Experimental Opinion Investigation Drugs 11 (2002) 787-800
14. Dahia P.L., and Grossman A.B. The molecular pathogenesis of corticotroph tumors. Endocrinology Review 20 (1999) 136-155
15. de Herder, W., Reijs, A., Kwekkeboom, D., Hofland, L., Nobels, F., Oei, H., Krenning, E., Lamberts, S., 1995. In: vivoimaging of pituitary tumours using a radiolabeled dopamineD2 receptor radioligand. Clinical Endocrinology (Oxf) 45, 1996, pp. 755-767.
16. Dong W., and Day R. Gene expression of proprotein convertases in individual rat anterior pituitary cells and their regulation in corticotrophs mediated by glucocorticoids. Endocrinology 143 (2002) 254-262
17. Feldman E.C., Bruyette D.S., and Nelson R.W. Plasma cortisol response to ketoconazoles administration in dogs with hyperadrenocorticism. American Journal Veterinary Medical Association 197 (1990) 71-78
18. Galac S., Kooistra H., Teske E., and Rijnberk A. Urinary corticoid/creatinine ratios in the differentiation between pituitary-dependent hyperadrenocorticism and hyperadrenocorticism due to adrenocortical tumour in the dog. Veterinary Quarterly 19 (1997) 17-20
19. Giros B., Solokoff P., Martres M.P., Riou J.F., Emorine L.J., and Schwartz J.C. Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature 342 (1989) 923-926
20. Gittoes N.J. Pituitary radiotherapy: current controversies. Trends Endocrinology Metabolism 16 (2005) 407-413
21. Goossens M., Feldman E., Theon A., and Koblik P. Efficacy of cobalt 60 radiotherapy in dogs with pituitary-dependent hyperadrenocorticism. Journal American Veterinarian Medical Association 212 (1998) 374-376
22. Gore A., Attardi B., and DeFranco D. Glucocorticoid repression of the reproductive axis: effects on GnRH and gonadotropin subunit mRNA levels. Molecular and Cellular Endocrinology 256 (2006) 40-48
23. Hereñú C., Brown O., Sosa Y., Morel G., Reggiani P., Bellini M., and Goya R. The neuroendocrine system as a model to evaluate experimental gene therapy. Current Gene Therapy 6 (2006) 125-129
24. Hereñú C., Cristina C., Rimoldi O., Becú-Villalobos D., Cambiaggi D., Portiansky E., and Goya R. Restorative effect of insulin-like growth factor-I gene therapy in the hypothalamus of senile rats with dopaminergic dysfunction. Gene Therapy 13 (2006) 1-9
25. Hofmann B., and Fahlbusch R. Treatment of Cushing's disease: a retrospective clinical study of the latest 100 cases. Frontiers Hormone Research 34 (2006) 158-184
26. Karl M., von Wichert G., Kempter E., Katz D., Reincke M., Monig H., Ali I., Stratakis C., Oldfield E., Chouros G., and Schulte H. Nelson's syndorme associated with somatic frame shift mutation in the glucocorticoid receptor gene. Journal Clinical Endocrinology Metabolism 81 (1996) 124-129
27. Kemppainen R.J., and Zenoble R.D. Non-dexametasone-suppressible, pituitary-dependent hyperadrenocorticism in dog. Journal American Veterinary Medical Association 187 (1985) 276-280
28. Kemppainen R.J., Zerbe C.A., and Sartin J.L. Regulation and secretion of proopiomelanocortin peptides from isolated perifused dog pituitary pars intermedia cells. Endocrinology 124 (1989) 2208-2217
29. Kintzer P., and Peterson M. Mitotane (o,p′-DDD) treatment of 200 dogs with pituitary- dependent hyperadrenocorticism. Journal Veterinary Internal Medicine 5 (1991) 182-190
30. Komanicky P., Spark R.F., and Melby J.C. Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis. Journal Clinical Endocrinology and Metabolism 47 (1978) 1042-1051
31. Kooistra H., Voorhout G., Mol J., and Rijnberk A. Correalation between impairment of glucocorticoid feedback and the size of the pituitary gland in dogs with pituitary-dependent hyperadrenocorticism. Journal of Endocrinology 152 (1997) 387-394
32. Labeur M., Arzt E., Stalla G., and Páez-Pereda M. New perspective in the treatment of Cushing's syndrome. Current Drug Targets-Immune, Endocrine and Metabolic Disorders 4 (2004) 29-36
33. Lado-Abeal J., Rodriguez-Arnao J., Newell-Price J.D., Perry L.A., Grossman A.B., Besser G.M., and Trainer P.J. Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels. Journal Clinical Endocrinology Metabolism 83 (1998) 3083-3088
34. Lamberts S., and McLoad R. Regulation of prolactin secretion at the level of the lactotroph. Physiology Review 70 (1990) 279-318
35. Laurent V., Kimble A., Peng B., Zhu P., Pintar J., Steiner D., and Lindberg I. Mortality in 7B2 null mice can be rescued by adrenalectomy: involvement of dopamine in ACTH hypersecretion. Medical Sciences 99 (2002) 3087-3092
36. Levy A., and Lightman S. Molecular defects in the pathogenesis of pituitary tumours. Frontiers in Neuroendocrinology 24 (2003) 94-127
37. Ling G., Stabenfeldt G., Comer K., Gribble D., and Schechter R. Canine hyperadrenocorticism: pre-treatment clinical and laboratory evaluation of 117 cases. Journal American Veterinary Medical Association 174 (1979) 1211-1215
38. Meij B., Mol J., Bevers M., and Rijnberk A. Alterations in anterior pituitary function of dogs with pituitary-dependent hyperadrenocorticism. Journal of Endocrinology 154 (1997) 505-512
39. Meij B., Voorhout G., and Rijnberk A. Progress in transsphenoidal hypophysectomy for treatment of pituitary- dependent hyperadrenocorticism in dogs and cats. Molecular Cellular Endocrinology 197 (2002) 89-96
40. Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. Journal Clinical Investigation 112 (2003) 1603-1618
41. Mercado-Asis L.B., Yasuda K., Murayama M., Mune T., Morita H., and Miura K. Beneficial effects of high daily dose bromocriptine in Cushing's disease. Endocrinology Japan 39 (1992) 385-395
42. Middleton D., Rijnberk A., Bevers M., Goos H., Beeftink E., Thijssen J., and Croughs R. Some functional and morphological aspects of canine corticotrophs. Frontiers Hormone Research 17 (1987) 10-17
43. Missale C., Nash S., Robinson S., Jaber M., and Caron M. Dopamine receptors: from structure to function. Physiology Review 78 (1998) 189-225
44. Munemura M., Cote T., Tsuruta K., Eskay R., and Kebabian J. The dopamine receptor in the intermediate lobe of the rat anterior pituitary gland: pharmacological characterization. Endocrinology 106 (1980) 1676-1683
45. Ooi G., Tawadros N., and Escalona R. Pituitary cell lines and their endocrine applications. Molecular and Cellular Endocrinology 228 (2004) 1-21
46. Páez-Pareda M., Kovalovsky D., Hopfner U., Theodoropoulou M., Pagotto U., Uhl E., Losa M., Stalla J., Grübler Y., Missale C., Arzt E., and Stalla G. Retinoic acid prevents experimental Cushing syndrome. Journal Clinical Investigation 108 (2001) 1123-1131
47. Paez-Pereda M., Artz E., and Stalla G. Cushing's syndrome: drug targets and therapeutic options. Experimental Opinion Therapy Patents 12 (2002) 1537-1546
48. Peterson M., Krieger D., Drucker W., and Halmi N. Immunocytochemical study of the hypophysis in 25 dogs with pituitary-dependent hyperadrenocorticism. Acta Endocrinological 101 (1982) 15-24
49. Peterson M., Orth D., Halmi N., Zielinski A., Davis D., Chavez F., and Drucker W. Plasma immunoreactive proopiomelanocortin peptides and cortisol in normal dogs and dogs with Addison's disease and Cushing's syndrome: basal concentrations. Endocrinology 119 (1986) 720-730
50. Petrossians P., Ronci N., Valdes Socin H., Kalife A., Stevenaert A., Bloch B., Tabarin A., and Beckers A. ACTH silent adenoma shrinking under cabergoline. European Journal Endocrinology 144 (2001) 51-57
51. Pivonello R., Faggiano A., Di Salle F., Filipella M., Lombardi G., and Colao A. Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. Journal Endocrinology Investigation 22 (1999) 860-865
52. Pivonello R., Ferone D., de Herder W., Kros J., del Basso de Caro M., Arvigo M., Annunziato L., Lombardi G., Colao A., Hofland L., and Lamberts S. Dopamine receptor expression and function in corticotroph pituitary tumors. Journal Clinical Endocrinology and Metabolism 89 (2004) 2452-2462
53. Rijnberk A., Mol J., Kwant M., and Croughs R. Efects of bromocriptine on corticotrophin, melanotrophin and corticosteroid secretion in dogs with pituitary-dependent hyperadrenocorticism. Journal of Endocrinology 118 (1988) 271-277
54. Rijnberk A., Van Wees A., and Mol J. Assessment of two tests for the diagnosis of canine hyperadrenocorticism. Veterinary Research 122 (1988) 178-180
55. Rothulzen J. Aging and the hypothalamus-pituitary-adrenocortical axis, with special referente to tje dog. Acta Endocrinological 125 (1991) 73-76
56. Saiardi A., Bozzi Y., Ja-Hyun Baik J., and Borrelli E. Antiproliferative role of dopamine: loss of D2 receptors causes hormonal dysfunction and pituitary hyperplasia. Neuron 19 (1997) 115-126
57. Shraga-Slutzky I., Shimon H., and Weinshtein R. Clinical and biochemical stabilization of Nelson's syndrome with long-term low-dose cabergoline treatment. Pituitary 9 (2006) 151-154
58. Sieber-Ruckstuhl N., Boretti F., Wenger M., Maser-Gluth C., and Reusch C. Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependant hyperadrenocorticism treated with trilostane. Domestic Animal Endocrinology 31 (2006) 63-75
59. Sonino N., and Boscaro M. Medical therapy for Cushing's disease. Endocrinology Metabolism Clinics North America 28 (1999) 211-222
60. Speert D., McClennen S., and Seasholtz A. Sexually dimorphic expression of corticotropin- releasing hormone-binding protein in the mouse pituitary. Endocrinology 143 (2002) 4730-4741
61. Tanaka S. Comparative aspects of intracellular proteolytic processing of peptide hormone precursors: studies of proopiomelanocortine processing. Zoological Science 20 (2003) 1183-1198
62. Thapar H., Kovacs K., Laws E., and Muller P. Pituitary adenomas: current concepts in classification, histopathology and molecular biology. The Endocrinologist 3 (1993) 39-57
63. Van Craenenbroeck K., De Bosscher K., Berghe W., Vanhoenacker P., and Haegeman G. Role of glucocorticoids in dopamine-related neuropsychiatric disorders. Molecular and Cellular Endocrinology 245 (2005) 10-22
64. Verhelst J., Abs R., Maiter D., Van den Bruel A., Vandeweghe M., Velkeniers B., et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. Journal of Clinical Endocrinology and Metabolism 842 (1999) 518-522
65. Westphal C., Muller L., Zhou A., Zhu X., Bonner-Weir S., Schambelan M., Steiner D., Lindberg I., and Leder P. The neuroendocrine protein 7B2 is required for peptide hormone processing in vivo and provides a novel mechanism for pituitary Cushing's disease. Cell 96 (1999) 689-700
66. Young E., Abelson J., and Lightman S. Cortisol pulsatility and its role in stress regulation and health. Frontiers in Neuroendocrinology 25 (2004) 69-76